SALT LAKE CITY — In this video, Jay Chhablani, MD, discusses preliminary data from the ArMaDa study of OCU410 gene therapy for geographic atrophy presented at the ARVO meeting.
In this phase 1/2 open-label dose-escalation trial, nine patients received a subretinal injection of low-dose, medium-dose or high-dose OCU410 (Ocugen), which delivers the RORA gene. After 6 months, there was a 21.4% reduction in GA lesion growth in treated eyes in three patients in the low-dose cohort compared with the fellow eye, according to Chhablani, principal investigator of Ocugen’s phase 2 data and